Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 341
- Registration Number
- NCT02277691
Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT02276274
TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [14C]-TAK-385 Oral SolutionDrug: TAK-385 TabletsDrug: [14C]-TAK-385 Solution for Intravenous Infusion
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT02252354
Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 964
- Registration Number
- NCT02221284
A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants
- First Posted Date
- 2014-08-18
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 74
- Registration Number
- NCT02219256
Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 18113
- Registration Number
- NCT02211638
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants
Phase 1
Terminated
- Conditions
- SafetyPharmacokineticsTolerabilityPharmacodynamics
- Interventions
- Drug: MLN3126 Matched Placebo
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 23
- Registration Number
- NCT02209506
Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2016-12-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 328
- Registration Number
- NCT02203916
Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2016-07-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 48
- Registration Number
- NCT02201056
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Phase 2
Completed
- Conditions
- Dengue Fever
- Interventions
- Drug: TDV Liquid Formulation 1Drug: TDV Liquid Formulation 2Drug: TDV IDT LyophilizedDrug: Placebo
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1002
- Registration Number
- NCT02193087
- Locations
- 🇺🇸
Advanced Clinical Research, Meridian, Idaho, United States
🇺🇸Clinical Research Atlanta, Stockbridge, Georgia, United States
🇺🇸Tekton Research, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath